We demonstrate that this vaccine yields orders of magnitude higher EGFRvIII-specific CD8+ T cell responses compared to PepvIII-KLH in vivo, and effectively protects against EGFRvIII-expressing tumor challenge, indicating its potential for translation to treat EGFRvIII-expressing tumors in human trials. Here, CD8A is linked to neoplasm.